IDH2抑制剂治疗复发性急性髓系白血病1例并文献复习

IDH2 inhibitor in the treatment of relapsed acute myeloid leukemia:a case report and literature review

复发/难治性急性髓性白血病(AML)患者的预后较差,国外的IDH2抑制剂恩西地平已在伴有IDH2突变的复发/难治性AML患者中显示出良好的临床疗效,但在我国目前尚未上市应用。现总结1例复发性AML患者,经常规化疗、维奈克拉联合阿扎胞苷治疗后二次复发,单药应用国产IDH2抑制剂TQB3455片5个月后达完全缓解,不良反应可耐受,体能状态良好,已持续完全缓解15个月。

The prognosis of patients with relapsed/refractory acute myeloid leukemia(AML) is generally poor. Importantly, for patients with IDH2-mutated AML, IDH2 inhibitor presents well-tolerated options in the treating of relapsed/refractory AML. The patient was an elderly woman with relapsed AML after conventional chemotherapy and venetoclax combined with azacitidine. After 5 months of single drug application with oral domestic IDH2 inhibitors TQB3455, the patient achieved complete remission and adverse events were well tolerated. The patient was in the good physical condition and had been in complete remission for 15 months.